Pace Life Sciences LLC, a full-service contract development and manufacturing organization (CDMO) and a subsidiary of Pace, a science and technology company, has acquired Biopharma Global (Biopharma), which specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs.
 
“Pace provides great value in our marketplace through our technical expertise and by meeting the strong commitments we make to our clients that rely on us to successfully advance their programs through development,” said Eric Roman, CEO of Pace. “The acquisition of Biopharma Global extends our reach further into regulatory strategy, guidance, and support in key therapeutic areas and greatly extends the reach of Pace into our markets.”
 
Expertise gained through the Biopharma acquisition allows Pace to extend the following capabilities to its clients:
 

• Regulatory strategy development
• Regulatory affairs submissions including FDA and EMA applications
• IND applications
• Orphan drug consulting
• Rare pediatric disease designations
• Fast track designations
• Biologics license applications

 
“The Biopharma Global team brings strong expertise in early drug development with sound regulatory strategy guidance and robust submission support,” notes Greg Kupp, president of Pace Life Sciences. “These services greatly enhance the continuity of offerings we provide to our clients and helps them to efficiently drive new drug candidates through the development process.”
 
In the coming months, Biopharma will transition to the Pace brand. The Biopharma operation is located in Vienna, Virginia, and joins Pace Life Sciences locations near Boston, MA, Salem, NH, Philadelphia, PA, Ann Arbor, MI, San Diego, CA, St. Paul, MN, and San Germán, PR.
 
Pace is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.